LifeMD, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
LFMD$2.37+3.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Telehealth revenue, net | $47,281,085 | $49,018,882 | $97,444,041 | $99,906,781 |
| Cost of telehealth revenue | 5,284,323 | 6,838,703 | 11,209,822 | 14,975,164 |
| Gross profit | 41,996,762 | 42,180,179 | 86,234,219 | 84,931,617 |
| Expenses | ||||
| Selling and marketing expenses | 28,035,947 | 22,151,114 | 57,910,807 | 44,424,036 |
| General and administrative expenses | 13,645,809 | 14,439,140 | 28,822,164 | 28,779,294 |
| Other operating expenses | 3,040,187 | 2,883,015 | 6,220,133 | 5,272,551 |
| Customer service expenses | 2,612,986 | 3,230,735 | 5,752,291 | 6,302,229 |
| Development costs | 1,791,434 | 1,823,061 | 3,587,497 | 3,682,110 |
| Total expenses | 49,126,363 | 44,527,065 | 102,292,892 | 88,460,220 |
| Operating loss from continuing operations | (7,129,601) | (2,346,886) | (16,058,673) | (3,528,603) |
| Interest income (expense), net | 45,660 | (660,787) | 102,136 | (1,124,425) |
| Loss from continuing operations before income taxes | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) |
| Income tax provision | - | - | - | - |
| Net loss from continuing operations | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) |
| Net income from discontinued operations | - | 1,893,084 | - | 3,886,506 |
| Net loss | (7,083,941) | (1,114,589) | (15,956,537) | (766,522) |
| Net income attributable to non-controlling interest of discontinued operations | - | 505,075 | - | 1,036,920 |
| Net loss attributable to LifeMD, Inc. | (7,083,941) | (1,619,664) | (15,956,537) | (1,803,442) |
| Preferred stock dividends | (776,562) | (776,562) | (1,553,125) | (1,553,125) |
| Net loss attributable to LifeMD, Inc. common stockholders | $(7,860,503) | $(2,396,226) | $(17,509,662) | $(3,356,567) |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders: | ||||
| Continuing operations | $(0.16) | $(0.09) | $(0.37) | $(0.14) |
| Discontinued operations | - | 0.03 | - | 0.07 |
| Basic loss per share | $(0.16) | $(0.05) | $(0.37) | $(0.08) |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders: | ||||
| Continuing operations | $(0.16) | $(0.09) | $(0.37) | $(0.14) |
| Discontinued operations | - | 0.03 | - | 0.07 |
| Diluted loss per share | $(0.16) | $(0.05) | $(0.37) | $(0.08) |
| Weighted average number of common shares outstanding: | ||||
| Basic | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |
| Diluted | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.